Cetrorelix: Physiology and What Research Reports

What Cetrorelix Is

Cetrorelix is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH, also written LH-RH) that acts as a receptor antagonist rather than an agonist. A 2023 review of cetrorelix in reproductive medicine described it as a GnRH antagonist used to prevent premature luteinising hormone (LH) surges during controlled ovarian stimulation (PMID 37223762). It is not a compound produced by the human body; the body produces GnRH itself, and cetrorelix is a laboratory-modified version designed to occupy the same pituitary receptor.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here describes a protocol, and doses appear only where a cited study reported them.

The Axis It Acts On

Endogenous GnRH is released in pulses from the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it stimulates release of LH and follicle-stimulating hormone (FSH). Those gonadotropins in turn act on the ovary or testis to drive follicular development, ovulation and sex steroid production. Because a competitive antagonist occupies the receptor without activating it, researchers have reported that gonadotropin output falls quickly rather than after an initial surge; pharmacokinetic-pharmacodynamic modelling in healthy volunteers characterised the suppression of both LH and testosterone by cetrorelix (PMID 10709155).

How Cetrorelix Is Measured and Studied

Most of what is known comes from three kinds of work: pharmacokinetic/pharmacodynamic (PK/PD) modelling, clinical fertility trials, and laboratory animal or cell studies.

Pharmacokinetic and Pharmacodynamic Modelling

Researchers built a PK/PD model of cetrorelix after subcutaneous administration in healthy premenopausal women, linking measured plasma concentrations to hormonal response (PMID 11180022). A separate population PK/PD analysis modelled cetrorelix concentrations together with testosterone in rats and dogs, allowing cross-species comparison of exposure and suppression (PMID 10801222). In the clinical setting, one study measured cetrorelix concentrations in both plasma and follicular fluid in women undergoing controlled ovarian stimulation for IVF, showing that the peptide can be quantified at the tissue compartment of interest (PMID 11998957).

Alternative Delivery Research

Because cetrorelix is a peptide and is not absorbed intact from the gut, formulation work has explored non-injectable routes. A 2025 study characterised lipid liquid crystal nanoparticles for intranasal delivery of cetrorelix and carried out pharmacokinetic studies in rats (PMID 40593190). Work of this kind is preclinical formulation science, not a clinical recommendation.

What the Clinical Literature Reports

The best-documented clinical context is assisted reproduction. Two large multicentre, multinational phase IIIb clinical experiences examined a 3 mg dose of cetrorelix for preventing premature LH surges and reported on both safety and efficacy (PMID 12831588). A later randomised controlled multicentre study examined reducing the cetrorelix dose within a multiple-dose antagonist protocol and reported on the impact on pregnancy rate and affordability (PMID 29376021). The 2023 review placed these uses in the broader context of reproductive medicine and the role of GnRH antagonists in stimulation cycles (PMID 37223762).

Animal and Laboratory Findings

Beyond fertility clinics, cetrorelix has been used as a research tool to interrogate ovarian biology. A 2026 study in cattle reported that cetrorelix suppressed the dominant follicle and synchronised follicular waves and ovulation (PMID 41395811). In mice, researchers reported that cetrorelix reduced cyclophosphamide-induced ovarian follicular destruction, a model used to study chemotherapy effects on the ovarian reserve (PMID 15117898). A 2019 histochemistry study examined how the GnRH antagonist cetrorelix affected Wnt signalling members in pubertal and adult mouse ovaries, pointing to molecular pathways downstream of gonadotropin withdrawal (PMID 31630211).

Separately, a 2025 oncology paper reported that cetrorelix promoted cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer (PMID 41458598). That finding sits at the cell and pathway level and does not by itself establish a clinical treatment role.

Cetrorelix Safety: What Studies Report

Adverse-event information in the verified literature comes chiefly from the fertility setting. The two large multicentre, multinational phase IIIb clinical experiences were framed explicitly around the safety and efficacy of a 3 mg dose of cetrorelix for preventing premature LH surges, and reported findings from large treated populations (PMID 12831588). The randomised multicentre study of a reduced cetrorelix dose reported outcomes including pregnancy rate, which is the efficacy endpoint most relevant to dose reduction questions (PMID 29376021). PK/PD studies in healthy volunteers characterised hormonal suppression — falls in LH and testosterone — as the expected pharmacological consequence of receptor blockade rather than as an off-target event (PMID 10709155). Readers looking for a full tolerability profile should note that this page summarises only the studies listed below; regulatory product labelling and a treating physician remain the appropriate sources for individual safety questions.

Why the Term Matters to Readers

Cetrorelix appears frequently in discussions of hormone-axis pharmacology because it is one of the clearest available examples of antagonism at the top of the hypothalamic-pituitary-gonadal axis. Understanding it helps clarify why GnRH agonists and GnRH antagonists behave differently, why animal studies use it to pause follicular development (PMID 41395811), and why formulation researchers have worked on non-injectable routes (PMID 40593190). Cetrorelix is a prescription pharmaceutical in the settings where it is approved; material sold for laboratory work is research-use-only and is not intended for human administration.

References

• Cetrorelix in reproductive medicine (F&S Reports, 2023)
• Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer (Frontiers in Oncology, 2025)
• Cetrorelix suppresses the dominant follicle and synchronizes follicular waves and ovulation in cattle (Biology of Reproduction, 2026)
• Intranasal Delivery of Cetrorelix Via Lipid Liquid Crystal Nanoparticles: Characterization and Pharmacokinetic Studies in Rats (AAPS PharmSciTech, 2025)
• Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women (Clinical Pharmacology and Therapeutics, 2000)
• The effect of GnRH antagonist cetrorelix on Wnt signaling members in pubertal and adult mouse ovaries (Histochemistry and Cell Biology, 2019)
• Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences (Reproductive BioMedicine Online, 2003)
• Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs (Pharmaceutical Research, 2000)
• The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice (Human Reproduction, 2004)
• Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF (Archives of Gynecology and Obstetrics, 2002)
• Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study (Clinical and Experimental Reproductive Medicine, 2017)
• Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers (Journal of Clinical Pharmacology, 2000)